fda semaglutide obesity What's New in Treatment? Novo Nordisk receives FDA approval

More than four in five PwO have made a serious attempt at weight loss but less than half of them would have lost 5% of their body weight over three years, and 70% of those that do are expected to regain their losses.11 This illustrates that regardless of the drivers of obesity, PwO are in an established state of pathological energy homeostasis that requires intensification of treatment beyond foundational lifestyle changes, and which often requires the use of anti-obesity medications (AOMs)

Please repost and share to help a fellow pharma professional!

In conversation with Ekta Batra, he breaks...

Novo Nordisks semaglutide added another win to its books, this time showing significantreductionsin symptoms in patients with heart failure with preserved ejection fraction (HFpEF)

SUPPORTS GLP-1 PRODUCTION These compounds help stimulate natural GLP-1 release, leading to better appetite control and improved insulin sensitivity